Evidence map›Paper›PMID 39589493›Full record

Trial reportAnnals of hematology2024

Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study.

Hongbing Ma, Yiwen Du, Jianjun Li, Jin Rao, Yong Guo, YunFan Yang, Duanzhong Zhang, Jia Wang, Yi Liao, Yuping Gong

Abstract readMulticenter StudyClinical Trial, Phase IIClinical Trial, Phase I
PubMed Publisher
In one paragraph

Trial report in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hongbing MaDepartment of hematology, West China Hospital, Sichuan University, No.37 Guoxuexiang St, 610041, Chengdu, China.
Yiwen DuDepartment of hematology, West China Hospital, Sichuan University, No.37 Guoxuexiang St, 610041, Chengdu, China.
Jianjun LiDepartment of hematology, West China Hospital, Sichuan University, No.37 Guoxuexiang St, 610041, Chengdu, China.
Jin RaoDepartment of hematology, Affiliated Hospital of Chengdu University, Chengdu, China.
Yong GuoDepartment of hematology, West China Hospital, Sichuan University, No.37 Guoxuexiang St, 610041, Chengdu, China.
YunFan YangDepartment of hematology, West China Hospital, Sichuan University, No.37 Guoxuexiang St, 610041, Chengdu, China.
Duanzhong ZhangDepartment of hematology, Dazhou Central Hospital, Dazhou, China.
Jia WangDepartment of hematology, The Second People's Hospital of Neijiang, Neijiang, China.
Yi LiaoDepartment of hematology, West China Hospital, Sichuan University, No.37 Guoxuexiang St, 610041, Chengdu, China.
Yuping GongDepartment of hematology, West China Hospital, Sichuan University, No.37 Guoxuexiang St, 610041, Chengdu, China. gongyuping@wchscu.cn.

Funding

1·3·5 project for disciplines of excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University 2023HXFH007Key Research and Development Project of Department of Science and Technology, Sichuan Province 2023YFS0307
6 · The paper itself

Abstract

Induction regimens with satisfactory remission rates are limited for patients with acute myeloid leukemia (AML) who are elderly or ineligible for intensive chemotherapy. This study is a single-arm, multicenter, prospective phase I/II study (registered with the Chinese Clinical Trial Registry as ChiCTR 2200059694 on May 8, 2022), aiming to evaluate the efficacy and safety of venetoclax plus decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (VD-CAG) for newly diagnosed AML patients who are elderly or ineligible for intensive chemotherapy. The primary endpoint was composite complete remission (CRc) after 1 cycle of induction chemotherapy. The secondary endpoints were measurable residual disease (MRD) by flow cytometry and adverse events. Forty patients(n = 40) received 1 cycle of the VD-CAG regimen for induction chemotherapy. The median age of the patients was 64 (55-81) years, and 10 patients (25%) had secondary AML. Our results showed that 1 cycle of VD-CAG had a high overall response rate of 97.5% and CRc of 95%, and all 10 patients with secondary AML achieved CRc. Moreover, the patients who achieved CRc had deep remission, with MRD-negativity of 71.1% and 54.2% by flow cytometry and molecular assessment, respectively. In addition, blood cell recovery was quick, with a median time to absolute neutrophil count ≥ 1.0 × 10

Indexed as

AclarubicinAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicCytarabineDecitabineGranulocyte Colony-Stimulating FactorLeukemia, Myeloid, AcuteSulfonamidesAgedAged, 80 and overFemaleHumansMaleMiddle AgedProspective StudiesRemission InductionAclarubicinBridged Bicyclo Compounds, HeterocyclicCytarabineDecitabineGranulocyte Colony-Stimulating FactorSulfonamidesvenetoclaxAclarubicinAcute myeloid leukemiaDecitabineInduction chemotherapyVenetoclax

Identifiers

PMID39589493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.